【IPO前哨】西子健康：抖音“捧红”的IPO，一场流量狂欢后的资本大考

Core Viewpoint - The company Hunan Xizi Health Group Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange, aiming to capitalize on the booming market for sports nutrition products driven by Douyin live streaming [2][9]. Group 1: Company Transformation and Performance - Xizi Health has transitioned from a third-party brand agent to a brand owner, with its own brand revenue share skyrocketing from 42.4% in 2023 to 97.3% in the first three quarters of 2025 [2][3]. - The company's gross margin has increased significantly from 44.4% in 2023 to 59.5% in the first three quarters of 2025, indicating improved profitability [2][3]. - The company has established a portfolio of four proprietary brands, with the core brand FoYes experiencing a staggering revenue growth of 364.2% in the first three quarters of 2025 [3][4]. Group 2: Revenue and Sales Channels - In the first three quarters of 2025, Douyin contributed 62.8% of the company's revenue, with overall online sales accounting for 98.9% of total revenue [4][5]. - The company's total revenue reached RMB 1.447 billion in 2023, projected to grow to RMB 1.692 billion in 2024, and already at RMB 1.609 billion in the first three quarters of 2025 [5][6]. Group 3: Financial Strategy and Risks - Xizi Health has conducted significant dividend payouts prior to its IPO, distributing approximately RMB 5.3 million, RMB 60 million, and RMB 48 million in 2023, 2024, and the first three quarters of 2025, respectively [6][7]. - The company faces structural risks due to its heavy reliance on online sales, with nearly 99% of revenue coming from direct online sales, primarily through Douyin [7][9]. - The rising customer acquisition costs, driven by increased competition in the live-streaming space, have led to a sales expense rate of 47.0% in the first three quarters of 2025, squeezing profit margins [7][9]. Group 4: Long-term Sustainability Challenges - The company's growth strategy heavily emphasizes marketing over research and development, with R&D expenses only accounting for 0.7% of revenue in the first three quarters of 2025, which is significantly lower than industry peers [8][9]. - Xizi Health's product offerings are primarily focused on mature categories like protein powder, with insufficient investment in innovation and core technology, raising concerns about long-term brand differentiation [9].